



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38005-078

1614
RECEIVED
OCT 15 2003
TECH CENTER 1600/2900

Applicant: Elisabeth DEFOSSA et al.

Confirmation No.

Appl. No.: 10/616,959

Examiner: Unassigned

Filing Date: July 11, 2003

Art Unit: Unassigned

Title: UREA- AND URETHANE-SUBSTITUTED ACYLUREAS, PROCESS
FOR THEIR PREPARATION AND THEIR USE

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

English translations of the foreign-language documents may not be readily available; however, the absence of such translations does not relieve the PTO from its duty to consider the submitted documents (37 CFR §1.98 and MPEP §609).

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) within three months from the filing date of the above-identified application, therefore, no fee is required in connection with its filing.


Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: Oct 10, 2003

Customer No. 26633
HELLER EHRMAN WHITE &
MCAULIFFE
1666 K Street, N.W., Suite 300
Washington, DC 20006
Telephone: (202) 912-2142
Facsimile: (202) 912-2020

By



Patricia D. Granados
Attorney for Applicant
Registration No. 33,683



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. GMB 0051-0051.
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

<i>Complete if Known</i>	
Application Number	Unassigned
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSSA et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0178

RECEIVED
2001 15 2003
INTER 1600/2900

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₈
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
o	A05	EP	0 221 847	A2	Ciba-Geigy AG	5/13/1987		
o	A06	WO	97/26265	A1	Novo Nordisk A/S	7/24/1997		
4	A07	WO	97/41097	A2	Dr. Reddy's Research Foundation	11/6/1997		
·	A08	WO	98/08871	A1	Novo Nordisk A/S	3/5/1998		
o	A09	WO	99/03861	A1	Novo Nordisk A/S	1/28/1999		
	A10	WO	99/15525	A1	Sanofi	4/1/1999		
1	A11	WO	00/40569	A1	Alizyme Therapeutics Limited	7/13/2000		
2	A12	WO	00/63208	A1	Novo Nordisk A/S	10/26/2000		
	A13	WO	00/64888	A1	Aventis Pharmaceuticals	11/2/2000		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC.



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/2026. GPO 2021-082.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

<i>Complete if Known</i>	
Application Number	Unassigned
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSS et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0178

1

15 200

15 2003
HR 1600/2900

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC



Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	Unassigned
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSSE et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0178

RECEIVED
15/01/2003
1600/2900

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A14 ^D	WO	00/64876	A1	Aventis Pharmaceuticals	11/2/2000		
	A15	WO	00/66585	A1	Neurogen Corp.	11/9/2000		
	A16 ^D	WO	00/71549	A1	Knoll Aktiengesellschaft	11/30/2000		
^D	A17	WO	00/78312	A1	Merck & Co., Inc.	12/28/2000		
	A18	WO	01/09111	A1	Eli Lilly & Co.	2/8/2001		
	A19	WO	01/83451	A1		11/8/2001		
^D	A20	WO	01/85695	A1	Bristol-Myers Squibb	11/15/2001		
	A21 ^D	WO	01/91752	A1	Merck & Co., Inc.	12/6/2001		
	A22 ^D	DE	10142734	A1	Aventis Pharma Deutschland GmbH	3/27/2003		

Examiner Signature:		Date Considered	
------------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC



OCT 10 2003 Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of 4

Complete if Known

Application Number	10/616,959
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSSA et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number 38005-0178

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A24	A. ASAKAWA et al., "Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice", Horm. Metab. Res., 2001, pp. 554-558, Vol. 33	
	A25	P. DRUECKES et al., "Photometric Microtiter Assay of Inorganic Phosphate in the Presence of Acid-Labile Organic Phosphates", Analytical Biochemistry, 1995, p. 173-177, Vol. 230	
	A26	H.D. ENGERS et al., "Kinetic mechanism of phosphorylase a. I. Initial velocity studies", Department of Biochemistry, University of Alberta, Edmonston 7, Alberta, January 12, 1970, pp. 746-754	
	A27	DANIEL W. LEE et al., "Leptin agonists as a potential approach to the treatment of obesity", Drugs of the Future, 2001, pp. 873-881, Vol. 26, No. 9	
	A28	HIROSHI OKADA et al., "Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas", Chem. Pharm. Bull., 1994, pp. 57-61, Vol. 42, No. 1	
	A29	JAVIER SALVADOR et al., "Perspectives in the therapeutic use of leptin", Expert Opin. Pharmacother, 2001, 2001, pp. 1615-1622, Vol. 2, No. 10	
	A30	PRAVENN TYLE, "Iontophoretic Devices for Drug Delivery", Pharmaceutical Research, 1986, pp. 318-326, Vol. 3, No. 6	
	A31	H.J.F. ZUNFT et al., "Carob Pulp Preparation for Treatment of Hypercholesterolemia", Advances In Natural Therapy", September/October 2001, pp. 231-236, Vol. 18, No. 5	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.